Relevant biomarkers and pathophysiology of chronic pain


Chronic pain affects 10-30 % of the population, puts a heavy burden on the suffering patient and on society, costs enormous sums of money (8.7 billion Euro/year in Sweden with 9 million inhabitants (SBU 2006)), and is difficult to treat. In addition, about 20-30 % of patients who are subjected to trauma/surgery or nerve lesions will develop chronic pain. Between 5-10 % will have pain that affects the activities of daily living, and about 1% suffers from severe pain. Thus, chronic pain must be considered as a wide spread disease in the world’s population. At present, no reliable methods exist (clinical signs, biomarkers, gene polymorphisms etc) for identification of the patient groups that will develop chronic pain after trauma. In addition, no biomarkers are known that can guide diagnosis and treatment of chronic pain. Thus, there is a large potential for new and important discoveries, in order to improve the situation for chronic pain patients.

In parallel with the clinical part within this project we include an activity directed to the identification of biomarkers associated with chronic pain in experimental animals as well as research focused on the development of peptidomimetics as candidate drugs for the treatment of neuropathic pain and other chronic pain states. The neurodegenerative element of the pathophysiology of chronic pain is one important focus in this activity.




Thematic area leader:

Prof.Torsten Gordh

Uppsala Berzelii Technology Centre for Neurodiagnostics | Email